Central Nervous System Relapse in Non-Hodgkin Lymphoma

Abstract

Patients with high- and intermediate-grade NHL carry a considerable risk of CNS relapse. Advanced stage is an additional independent risk factor. The role of CNS prophylaxis seems to be disappointing, but a retrospective analysis cannot be conclusive. Prognosis after CNS relapse is poor.

Prognostic factors in 140 adult patients with non-Hodgkin's lymphoma with systemic central nervous system (CNS) involvement. A single centre analysis

“…The incidence of CNS manifestations at diagnosis from our series of 30/2651 patients (1.2%) is in line with the results from Bollen et al (1997). The incidence at diagnosis varies most of all with the histological subtypes, and is highest in Burkitt's lymphoma and Burkitt's leukemia.…”

“…8.1.3 Risk factors for central nervous system recurrence in non-Hodgkin's lymphoma and the value of CNS prophylaxis CNS prophylaxis is clearly warranted in Burkitt's and lymphoblastic lymphomas based on the high CNS relapse rates of 17%-47% reported from several studies (Ersboll et al 1985, Liang et al 1990, Keldsen et al 1996, Bollen et al 1997, Tomita et al 2000 and from our study (Hollender et al 2000 and2002) and the reduced incidences in studies with both systemic and i.t. prophylaxis both in children and adults (Murphy et al 1986, Patte et al 1991, Reiter et al 1992, Soussain et al 1995, Mead et al 2002, Pees et al 1992, Smeland et al 2004.…”

Prognostic factors in 140 adult patients with non-Hodgkin's lymphoma with systemic central nervous system (CNS) involvement. A single centre analysis

“…The incidence of CNS manifestations at diagnosis from our series of 30/2651 patients (1.2%) is in line with the results from Bollen et al (1997). The incidence at diagnosis varies most of all with the histological subtypes, and is highest in Burkitt's lymphoma and Burkitt's leukemia.…”

“…8.1.3 Risk factors for central nervous system recurrence in non-Hodgkin's lymphoma and the value of CNS prophylaxis CNS prophylaxis is clearly warranted in Burkitt's and lymphoblastic lymphomas based on the high CNS relapse rates of 17%-47% reported from several studies (Ersboll et al 1985, Liang et al 1990, Keldsen et al 1996, Bollen et al 1997, Tomita et al 2000 and from our study (Hollender et al 2000 and2002) and the reduced incidences in studies with both systemic and i.t. prophylaxis both in children and adults (Murphy et al 1986, Patte et al 1991, Reiter et al 1992, Soussain et al 1995, Mead et al 2002, Pees et al 1992, Smeland et al 2004.…”

Central nervous system involvement in patients with mantle cell lymphoma

“…Generally, CNS prophylaxis is recommended for patients with high-grade NHL or for highrisk patients with intermediate-grade lymphomas [12,16,33], but its benefit has not been proven [4]. In our study, one patient (case 3) had achieved prophylactic treatment with intrathecal methotrexate injections, but still developed CNS infiltration within 4 months.…”

“…As in other lymphomas [4,32], the prognosis of MCL patients with CNS involvement seems to be poor. Most of the patients die within 2 months from the diagnosis of CNS involvement ( Table 3).…”

CNS Prophylaxis and Treatment in Non-Hodgkin's Lymphoma: Variation in Practice and Lessons from the Literature

“……”

Prognostic factors in 140 adult patients with non-Hodgkin's lymphoma with systemic central nervous system (CNS) involvement. A single centre analysis

“…The incidence of CNS manifestations at diagnosis from our series of 30/2651 patients (1.2%) is in line with the results from Bollen et al (1997). The incidence at diagnosis varies most of all with the histological subtypes, and is highest in Burkitt's lymphoma and Burkitt's leukemia.…”

“…8.1.3 Risk factors for central nervous system recurrence in non-Hodgkin's lymphoma and the value of CNS prophylaxis CNS prophylaxis is clearly warranted in Burkitt's and lymphoblastic lymphomas based on the high CNS relapse rates of 17%-47% reported from several studies (Ersboll et al 1985, Liang et al 1990, Keldsen et al 1996, Bollen et al 1997, Tomita et al 2000 and from our study (Hollender et al 2000 and2002) and the reduced incidences in studies with both systemic and i.t. prophylaxis both in children and adults (Murphy et al 1986, Patte et al 1991, Reiter et al 1992, Soussain et al 1995, Mead et al 2002, Pees et al 1992, Smeland et al 2004.…”

Central nervous system involvement in patients with mantle cell lymphoma

“…Generally, CNS prophylaxis is recommended for patients with high-grade NHL or for highrisk patients with intermediate-grade lymphomas [12,16,33], but its benefit has not been proven [4]. In our study, one patient (case 3) had achieved prophylactic treatment with intrathecal methotrexate injections, but still developed CNS infiltration within 4 months.…”

“…As in other lymphomas [4,32], the prognosis of MCL patients with CNS involvement seems to be poor. Most of the patients die within 2 months from the diagnosis of CNS involvement ( Table 3).…”

CNS Prophylaxis and Treatment in Non-Hodgkin's Lymphoma: Variation in Practice and Lessons from the Literature

“……”

Prognostic factors in 140 adult patients with non-Hodgkin's lymphoma with systemic central nervous system (CNS) involvement. A single centre analysis

“…The incidence of CNS manifestations at diagnosis from our series of 30/2651 patients (1.2%) is in line with the results from Bollen et al (1997). The incidence at diagnosis varies most of all with the histological subtypes, and is highest in Burkitt's lymphoma and Burkitt's leukemia.…”

“…8.1.3 Risk factors for central nervous system recurrence in non-Hodgkin's lymphoma and the value of CNS prophylaxis CNS prophylaxis is clearly warranted in Burkitt's and lymphoblastic lymphomas based on the high CNS relapse rates of 17%-47% reported from several studies (Ersboll et al 1985, Liang et al 1990, Keldsen et al 1996, Bollen et al 1997, Tomita et al 2000 and from our study (Hollender et al 2000 and2002) and the reduced incidences in studies with both systemic and i.t. prophylaxis both in children and adults (Murphy et al 1986, Patte et al 1991, Reiter et al 1992, Soussain et al 1995, Mead et al 2002, Pees et al 1992, Smeland et al 2004.…”

Central nervous system involvement in patients with mantle cell lymphoma

“…Generally, CNS prophylaxis is recommended for patients with high-grade NHL or for highrisk patients with intermediate-grade lymphomas [12,16,33], but its benefit has not been proven [4]. In our study, one patient (case 3) had achieved prophylactic treatment with intrathecal methotrexate injections, but still developed CNS infiltration within 4 months.…”

“…As in other lymphomas [4,32], the prognosis of MCL patients with CNS involvement seems to be poor. Most of the patients die within 2 months from the diagnosis of CNS involvement ( Table 3).…”

CNS Prophylaxis and Treatment in Non-Hodgkin's Lymphoma: Variation in Practice and Lessons from the Literature

“……”